S100A16 and glioblastoma: The result suggested that S100A16 was up-regulated in GBM and LGG, as well as bladder urothelial carcinoma (BLCA), cervical squamous cell carcinoma (CESC), colon adenocarcinoma (COAD) et.al, whereas down-regulated in adrenocortical carcinoma (ACC), esophageal carcinoma (ESCA), and kidney Chromophobe (KICH) et.al.